Moderna stock jumps 50% as Merck cancer vaccine trial succeeds
Moderna stock (MRNA) enters a pivotal moment. The daily chart remains firmly bullish, while intraday timeframes show a brief pullback. On August 19, positive Phase 3 INTerpath-001 results from Moderna and Merck triggered headlines of a 50% surge, a move far beyond the latest technical snapshot.
Key takeaways
- The daily chart stays bullish, with the August 18 close of 62.96 above the EMA20, EMA50, and EMA200.
- Daily RSI14 sits at 55.04, leaving room before overbought conditions.
- The 1H MACD has turned negative, signaling a short-term pullback into the close.
- On August 19, Moderna and Merck reported positive INTerpath-001 Phase 3 results, with headlines describing a 50% surge.
- Daily resistance starts near 64.18, with the upper Bollinger Band at 65.39.
Moderna Stock Daily Trend: Structure Still Favors the Bulls
The daily trend for Moderna stock remains clearly bullish. On August 18, the close of 62.96 sat above the EMA20 at 60.74, the EMA50 at 59.54, and the EMA200 at 49.29. That stacked alignment is a textbook uptrend signature: shorter-term averages above longer-term ones, with the 200-day EMA far below current price. It reflects the strong six-month advance already noted in recent coverage of Moderna shares climbing 44.2% and touching 63.36.
โฆ Continue reading the full article at the original source below.
